Discover how Mounjaro helped people lose weight faster than Ozempic in a new study. Learn more about these results and get inspired!

A new real-world study compared Mounjaro and Ozempic for weight loss. It found Mounjaro outperformed Ozempic in several ways:

  • More people on Mounjaro hit weight loss goals versus those on Ozempic.
  • Overall, the Mounjaro group lost more weight than the Ozempic group.

This is the first direct comparison of the two drugs for weight loss using real patient data.

Prior studies sponsored by the drugmakers compare each one individually to placebo. But this new research analyzed medical records to directly stack Mounjaro against Ozempic.

The takeaway – in real-world use, Mounjaro appears more effective for weight loss than Ozempic based on the study’s findings. More patients hit weight loss benchmarks on Mounjaro.

A new real-world study in JAMA Internal Medicine compared Eli Lilly’s Mounjaro (tirzepatide) and Novo Nordisk’s Ozempic (semaglutide) for weight loss in people with obesity.

The results show Mounjaro outperformed Ozempic across weight loss benchmarks and overall pounds lost.

Both are GLP-1 drugs, which control blood sugar and appetite by mimicking gut hormones. They’re FDA-approved for type 2 diabetes and often prescribed off-label for obesity.

In prior studies, Ozempic showed up to 16% weight loss, while some lost over 20% on Mounjaro. But differences in trial design made direct comparison impossible.

This real-world data now suggests Mounjaro is more effective for weight loss overall. As Dr. Beverly Tchang explains:

“This reinforces what we see in clinical practice – people lose more weight on tirzepatide than semaglutide.”

By analyzing actual patient records rather than a controlled study, these findings reflect what doctors observe in real-world use.

Tirzepatide Patients 3 Times More Likely to Achieve 15%+ Weight Loss

Key Weight Loss Findings

  • Patients on Mounjaro were over 2x as likely to lose 10% body weight vs Ozempic.
  • They were 3x as likely to lose 15% body weight compared to Ozempic.
  • At 3, 6, and 12 months, total weight loss was greater with Mounjaro.
  • The gap widened over time – after 1 year, Mounjaro patients lost 15% weight, Ozempic 8%.

As Dr. Ty Gluckman explains, having timely real-world data is crucial to inform patient care, especially for newer drugs like Mounjaro. This analysis offers valuable insights into how these medications perform outside controlled trials.

About the Research

  • Researchers analyzed electronic records of over 40,000 people prescribed Mounjaro or Ozempic.
  • They matched similar patients taking each drug, leaving a final cohort of 18,386.
  • Average age was 52, mostly female (70%) and white (77%).
  • 12% were Black, 2% Asian. Over half had type 2 diabetes.

By tapping into prescriber databases rather than a controlled study, this reflects real-world use and effectiveness. The large sample size also adds confidence in the results.

In plain terms, this study found Mounjaro appears more effective than Ozempic for weight loss based on patient data, with higher likelihood of hitting 10-15% weight loss goals.

No Major Difference in Safety Observed

The study also looked at whether Mounjaro or Ozempic led to more adverse health events.

Both can cause common GI issues like nausea, diarrhea, and vomiting. More serious problems like bowel obstruction have also occurred.

However, Mounjaro and Ozempic showed similar rates of adverse effects overall, according to the research.

Moderate to severe outcomes seen included:

  • Bowel obstruction
  • Gastroparesis
  • Pancreatitis
  • Gallstones

As lead author Dr. Tricia Rodriguez explains:

“We didn’t find a difference in rates of severe GI events between the two medications.”

This real-world data is reassuring on the safety profiles between Mounjaro and Ozempic. Larger studies over longer periods can further confirm comparative risks.

This real-world study is the first to directly compare Mounjaro and Ozempic using patient healthcare data.

The results show Mounjaro delivered better weight loss outcomes:

  • Patients were 2x as likely to lose 10% body weight on Mounjaro.
  • They were 3x as likely to lose 15% body weight on Mounjaro.

In terms of safety, both medications had similar rates of gastrointestinal side effects during the study period.

This analysis provides valuable insights from actual clinical use, beyond controlled trials. The large sample size adds confidence in the results.

In plain terms, Mounjaro outperformed Ozempic on weight loss benchmarks while showing a comparable safety profile. More research can further confirm the real-world effectiveness and risks over longer periods.

More resources:

Leave A Reply